Overview

Effect of Levcromakalim in Individuals With Migraine Pretreated With Erenumab

Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
An outstanding scientific question, that merits further investigation, is whether dilation of intracranial arteries is implicated in the pathogenesis of cephalic pain in migraine. Here, we hypothesize that experimentally-induced dilation of intracranial arteries using intravenous infusion of levcromakalim (a potent vasodilator) induces cephalic pain with migraine-like features in people with migraine, who prior to the infusion are administered erenumab (anti-calcitonin gene-related peptide (CGRP) receptor monoclonal antibody).
Phase:
N/A
Details
Lead Sponsor:
Danish Headache Center
Collaborator:
Novartis
Treatments:
Cromakalim